Outlook Therapeutics (OTLK) Research & Development: 2015-2024
Historic Research & Development for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to $41.8 million.
- Outlook Therapeutics' Research & Development rose 2.25% to $7.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $26.3 million, marking a year-over-year increase of 10.66%. This contributed to the annual value of $41.8 million for FY2024, which is 57.88% up from last year.
- Per Outlook Therapeutics' latest filing, its Research & Development stood at $41.8 million for FY2024, which was up 57.88% from $26.5 million recorded in FY2023.
- In the past 5 years, Outlook Therapeutics' Research & Development registered a high of $42.3 million during FY2022, and its lowest value of $26.3 million during FY2020.
- Its 3-year average for Research & Development is $36.8 million, with a median of $41.8 million in 2024.
- Its Research & Development has fluctuated over the past 5 years, first crashed by 37.51% in 2023, then surged by 57.88% in 2024.
- Over the past 5 years, Outlook Therapeutics' Research & Development (Yearly) stood at $26.3 million in 2020, then spiked by 47.89% to $39.0 million in 2021, then grew by 8.66% to $42.3 million in 2022, then plummeted by 37.51% to $26.5 million in 2023, then skyrocketed by 57.88% to $41.8 million in 2024.